Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management

BACKGROUND: Dupilumab is a humanized monoclonal antibody targeting the IL4/IL13 signaling pathway, already used for atopic dermatitis and chronic rhinitis with nasal polyps, recently approved for severe type-2 asthma. Its efficacy has been demonstrated in randomized control trials. The aim of our st...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpagnano, Giovanna Elisiana, Scioscia, Giulia, Buonamico, Enrico, Lacedonia, Donato, Diaferia, Fabrizio, Capozza, Elena, Lepore, Giorgia, Resta, Onofrio, Foschino Barbaro, Maria Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848342/
https://www.ncbi.nlm.nih.gov/pubmed/35280851
http://dx.doi.org/10.4081/mrm.2022.797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848342/
https://www.ncbi.nlm.nih.gov/pubmed/35280851
http://dx.doi.org/10.4081/mrm.2022.797

Ejemplares similares